Developer docs
API playgroundTry for free, no card

Search company profiles

Neuroservices-Alliance

Full company profile

uuid000vwv8

Namestring
Neuroservices-Alliance
Legal namestring
NEUROSERVICES ALLIANCE
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Neuroservices-Alliance (NsA) is a private French Contract Research Organization founded in 2018 as a consortium of complementary CNS-focused CROs, integrating wholly-owned subsidiaries (Neuroservice, Neuroservice USA) with jointly-controlled partner platforms (Key-Obs, AnaBios, Synaxys, E-Phys). The company delivers preclinical CNS and pain electrophysiology services to pharmaceutical and biotechnology clients across the in vitro to in vivo continuum: cell electrophysiology (patch-clamp, MEA, HD-MEA via MaxWell Biosystems MaxTwo, Fura-2 calcium imaging), 3D neural organoids, ex vivo brain slice electrophysiology on rodent and human tissue, in vivo brain electrophysiology (LFP, EEG, optogenetics), and in vivo spinal cord and DRG electrophysiology. Therapeutic area coverage spans pain, Alzheimer's, Parkinson's, Huntington's, ALS, epilepsy, schizophrenia, ADHD, autism, anxiety/PTSD, and addiction.

Revenue is generated exclusively through project-based contract research engagements; pricing is fully quote-based and not publicly disclosed. Distribution is enterprise field sales driven by scientific liaisons, supplemented by active participation in flagship scientific conferences (SfN, BIO, BIO Japan, IASP, SLAS, ISSCR), a multi-language webinar and scientific blog program, and direct website inquiry channels. The customer base is anchored in large pharmaceutical companies (Lilly, Roche, Biogen, Merck, Lundbeck, CHDI Foundation) but also includes emerging biotech (Latigo Biotherapeutics) and academic research institutions (Scripps Research). Founded by Bruno Buisson (President & CSO) and Olivier Toury (CEO), the company operates from Le Puy Sainte Reparade, France, with additional sites in San Diego, USA and Bordeaux, France, and has served 300+ clients with 1500+ cumulative studies since inception.

Short descriptiontext

Neuroservices-Alliance is a private French CRO consortium delivering preclinical CNS and pain electrophysiology services—from cell patch-clamp to in vivo spinal cord and human tissue studies—to pharmaceutical and biotechnology clients worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS electrophysiology services, preclinical drug discovery, contract research organization, neuropharmacology testing, patch clamp recording
Industry2 codes
1Preclinical CROs (Discovery/Pharmacology/DMPK)
CodeHLAGAAABPrimaryYes
2Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
CodeHLAGAAALPrimaryNo
NAICS code3 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Preclinical Contract Research Services
TypeProfessional Services
Description

Neuroservices-Alliance operates as a Contract Research Organization (CRO) providing CNS and pain preclinical development services to pharmaceutical and biotech companies. Revenue is generated through project-based contracts for electrophysiology studies, assay development, and pharmacological characterization.

neuroservices-alliance.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Neuroservices-Alliance is a Contract Research Organization (CRO) operating as a consortium of complementary CNS electrophysiology platforms that provide preclinical drug discovery services to pharmaceutical and biotech companies. Its core offerings span cell electrophysiology (patch-clamp, MEA, calcium imaging), 3D neural organoids, ex vivo brain slice electrophysiology, in vivo brain electrophysiology, and in vivo spinal cord and DRG electrophysiology, supporting CNS and pain therapeutic programs from target validation through translational studies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 300+ worldwide clients served
+3 more records
Product overview1 text field

Neuroservices-Alliance is a CNS Electrophysiology Contract Research Organization (CRO) operating as a consortium of complementary expert platforms that provide integrated preclinical drug discovery services. The company offers a portfolio of specialized service platforms including: Cell Electrophysiology (patch-clamp, MEA, calcium imaging), Organoids, Brain Slice Electrophysiology, In Vivo Brain Electrophysiology, and In Vivo Spinal Cord & DRG Electrophysiology. These platforms are supported by key techniques such as HD-MEA (via MaxWell Biosystems partnership), Calcium Imaging, and Patch-Clamp recording. Through partner platforms including AnaBios (human tissue assays), Key-Obs (in vivo behavioral models), and Synaxys (organoid services), the company delivers comprehensive CNS and pain drug discovery solutions spanning in vitro cell electrophysiology, ex vivo brain slice studies, and in vivo animal model services. The company serves therapeutic areas including ADHD, ALS, Alzheimer's, anxiety/PTSD, autism, epilepsy, Huntington's, pain, Parkinson's, and schizophrenia.

Product and service4 records
1Cell Electrophysiology Platform
CategoryCore service platform
Description

Electrophysiology services capturing accurate data from human and animal neuronal cultures using patch clamp, MEA, and calcium imaging for drug discovery programs. Targets pharmaceutical and biotech clients.

2Organoids Platform
CategoryCore service platform
Description

3D human-derived neural organoid services capturing complex network activity and translational functional responses for CNS drug discovery.

3Brain Slice Electrophysiology Platform
CategoryCore service platform
Description

Ex vivo brain slice recording services using acute rodent and human brain slices for comprehensive CNS insights in preclinical research.

4In Vivo Brain Electrophysiology Platform
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-03
Description

Partnership to advance human-relevant CNS research. Co-hosted networking event at SfN 2025 in San Diego. Combines FUJIFILM's iCell neuronal products with Neuroservices-Alliance's electrophysiology expertise.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2024-10-16
Description

Strategic partnership announced to enhance CNS drug discovery services through complementary capabilities.

Strategic tierCoreTypeTechnology or Integration
Description

Strategic partnership providing MaxWell Biosystems' HD-MEA technology (MaxTwo system) for high-content electrophysiology recording of human iPSC-derived neurons and other neuron cultures. Enables sub-cellular resolution recording with 26K+ electrodes per well.

Strategic tierCoreTypeTechnology or Integration
Description

Collaboration offering RealDRGTM cells from Anatomic for human DRG neuron research. Neuroservices-Alliance conducts studies using these cells for pain drug discovery applications.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Preferred partner for in vivo models and behavioral tests. Key-Obs provides CNS disease models, behavioral phenotyping of transgenic mice, and screening assays for psychiatric, neurodegenerative, and other CNS disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Member company located in San Diego specializing in human tissue-based assays for safety and efficacy evaluation. Provides ex vivo human data including human DRG neurons from normal and chronic pain donors for pain drug discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded by Sophie Pautot, Synaxys specializes in preclinical in vitro human models including 3D engineered neuronal cell cultures for functional monitoring of brain models.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with neurosurgeons from CHU of Bordeaux providing access to human brain tissue from resection surgeries for patch clamp recordings on pyramidal neurons, dentate gyrus neurons, and interneurons.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AnaBios is a US-based CRO specializing in human tissue-based assays for drug discovery, including human DRG neurons and cardiomyocytes. It operates both as an integrated partner within the Neuroservices-Alliance consortium and as a direct provider of pain and safety pharmacology services to the same biopharma customers.

TypeDirect peer
Description

Porsolt is a French preclinical CRO offering CNS pharmacology services including behavioral models and electrophysiology for CNS drug discovery. It is a comparable small-to-mid sized French CNS CRO with overlapping customer base and similar service lines, particularly in behavioral and translational CNS pharmacology.

TypeDirect peer
Description

PsychoGenics is a US-based preclinical CRO specializing in CNS behavioral and electrophysiology services for psychiatric and neurodegenerative drug discovery. It is the closest direct competitor to Neuroservices-Alliance, operating in the same CNS preclinical niche with overlapping customer base in big-pharma neurology and psychiatry programs.

TypeBroad incumbent
Description

Eurofins is one of the world's largest testing and contract research services groups, with a dedicated Discovery/CNS pharmacology arm offering electrophysiology and in vivo CNS studies. It overlaps with Neuroservices-Alliance on CNS preclinical services but competes mainly via scale, integrated platforms, and global lab footprint.

TypeBroad incumbent
Description

Labcorp Drug Development is a global CRO offering preclinical and clinical research services including CNS pharmacology and safety assessment. It competes with Neuroservices-Alliance primarily at the enterprise level for integrated discovery-to-IND programs, but is much broader in scale and service scope.

TypeBroad incumbent
Description

Charles River is a global CRO with extensive preclinical CNS capabilities including safety assessment, electrophysiology, and in vivo pharmacology. It competes with Neuroservices-Alliance for enterprise-level CNS preclinical contracts but offers a far broader non-clinical service menu including toxicology and regulatory support.

TypeDirect peer
Description

QPS is a mid-sized CRO with strong CNS and pain preclinical capabilities including electrophysiology, translational biomarkers, and in vivo CNS models. It is comparable to Neuroservices-Alliance in therapeutic-area focus and customer base, while also operating its own bioanalytical and clinical services lines.

TypeBroad incumbent
Description

Evotec is a global drug discovery contract research and development organization offering CNS electrophysiology, in vitro/in vivo pharmacology, and integrated discovery services. It is comparable as a much larger broad-line CRO with overlapping CNS preclinical capabilities and similar biopharma customers, but with a significantly wider service portfolio.

TypeDirect peer
Description

SynapCell is a French preclinical CRO specialized in CNS electrophysiology, particularly in vivo and ex vivo recordings for epilepsy and neurodegenerative disease drug discovery. It is highly comparable to Neuroservices-Alliance in scale, therapeutic-area focus, and electrophysiology service offering, and operates in the same European CNS CRO segment.

TypeEmerging player
Description

Gubra is a Danish preclinical CRO offering in vivo pharmacology, metabolic disease models, and CNS-related services. It is comparable to Neuroservices-Alliance as a mid-sized specialty CRO expanding into CNS and pain drug discovery, though it has stronger positioning in metabolic and endocrine areas.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries6 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neuroservices-Alliance

Preclinical Contract Research Servicesneuroservices-alliance.com

Neuroservices-Alliance is a private French CRO consortium delivering preclinical CNS and pain electrophysiology services—from cell patch-clamp to in vivo spinal cord and human tissue studies—to pharmaceutical and biotechnology clients worldwide.

What Neuroservices-Alliance does

Neuroservices-Alliance (NsA) is a private French Contract Research Organization founded in 2018 as a consortium of complementary CNS-focused CROs, integrating wholly-owned subsidiaries (Neuroservice, Neuroservice USA) with jointly-controlled partner platforms (Key-Obs, AnaBios, Synaxys, E-Phys). The company delivers preclinical CNS and pain electrophysiology services to pharmaceutical and biotechnology clients across the in vitro to in vivo continuum: cell electrophysiology (patch-clamp, MEA, HD-MEA via MaxWell Biosystems MaxTwo, Fura-2 calcium imaging), 3D neural organoids, ex vivo brain slice electrophysiology on rodent and human tissue, in vivo brain electrophysiology (LFP, EEG, optogenetics), and in vivo spinal cord and DRG electrophysiology. Therapeutic area coverage spans pain, Alzheimer's, Parkinson's, Huntington's, ALS, epilepsy, schizophrenia, ADHD, autism, anxiety/PTSD, and addiction.

Revenue is generated exclusively through project-based contract research engagements; pricing is fully quote-based and not publicly disclosed. Distribution is enterprise field sales driven by scientific liaisons, supplemented by active participation in flagship scientific conferences (SfN, BIO, BIO Japan, IASP, SLAS, ISSCR), a multi-language webinar and scientific blog program, and direct website inquiry channels. The customer base is anchored in large pharmaceutical companies (Lilly, Roche, Biogen, Merck, Lundbeck, CHDI Foundation) but also includes emerging biotech (Latigo Biotherapeutics) and academic research institutions (Scripps Research). Founded by Bruno Buisson (President & CSO) and Olivier Toury (CEO), the company operates from Le Puy Sainte Reparade, France, with additional sites in San Diego, USA and Bordeaux, France, and has served 300+ clients with 1500+ cumulative studies since inception.

Neuroservices-Alliance firmographics

Firmographics
Name
Neuroservices-Alliance
Legal name
NEUROSERVICES ALLIANCE
Website
https://neuroservices-alliance.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Neuroservices-Alliance is a private French CRO consortium delivering preclinical CNS and pain electrophysiology services—from cell patch-clamp to in vivo spinal cord and human tissue studies—to pharmaceutical and biotechnology clients worldwide.
Ownership category
akta.pro rank

Neuroservices-Alliance industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro primary industry
Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB)
akta.pro secondary industry
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

Keywords

  • CNS electrophysiology services
  • Preclinical drug discovery
  • Contract research organization
  • Neuropharmacology testing
  • Patch clamp recording

Where Neuroservices-Alliance is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Neuroservices-Alliance business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Preclinical Contract Research Services: Neuroservices-Alliance operates as a Contract Research Organization (CRO) providing CNS and pain preclinical development services to pharmaceutical and biotech companies. Revenue is generated through project-based contracts for electrophysiology studies, assay development, and pharmacological characterization.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Neuroservices-Alliance product offering

Product offering

Core offering

Neuroservices-Alliance is a Contract Research Organization (CRO) operating as a consortium of complementary CNS electrophysiology platforms that provide preclinical drug discovery services to pharmaceutical and biotech companies. Its core offerings span cell electrophysiology (patch-clamp, MEA, calcium imaging), 3D neural organoids, ex vivo brain slice electrophysiology, in vivo brain electrophysiology, and in vivo spinal cord and DRG electrophysiology, supporting CNS and pain therapeutic programs from target validation through translational studies.

Product overview

Neuroservices-Alliance is a CNS Electrophysiology Contract Research Organization (CRO) operating as a consortium of complementary expert platforms that provide integrated preclinical drug discovery services. The company offers a portfolio of specialized service platforms including: Cell Electrophysiology (patch-clamp, MEA, calcium imaging), Organoids, Brain Slice Electrophysiology, In Vivo Brain Electrophysiology, and In Vivo Spinal Cord & DRG Electrophysiology. These platforms are supported by key techniques such as HD-MEA (via MaxWell Biosystems partnership), Calcium Imaging, and Patch-Clamp recording. Through partner platforms including AnaBios (human tissue assays), Key-Obs (in vivo behavioral models), and Synaxys (organoid services), the company delivers comprehensive CNS and pain drug discovery solutions spanning in vitro cell electrophysiology, ex vivo brain slice studies, and in vivo animal model services. The company serves therapeutic areas including ADHD, ALS, Alzheimer's, anxiety/PTSD, autism, epilepsy, Huntington's, pain, Parkinson's, and schizophrenia.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cell Electrophysiology Platform Electrophysiology services capturing accurate data from human and animal neuronal cultures using patch clamp, MEA, and calcium imaging for drug discovery programs. Targets pharmaceutical and biotech clients.
  • Organoids Platform 3D human-derived neural organoid services capturing complex network activity and translational functional responses for CNS drug discovery.
  • Brain Slice Electrophysiology Platform Ex vivo brain slice recording services using acute rodent and human brain slices for comprehensive CNS insights in preclinical research.
  • In Vivo Brain Electrophysiology Platform

Quantifiable outcome

  • 300+ worldwide clients served
  • +3 more outcomes

Companies that use Neuroservices-Alliance

Customer profile

Named customers11 records

Segments3 records

Ideal customer profiles3 records

Neuroservices-Alliance technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Neuroservices-Alliance partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • FUJIFILM Cellular DynamicscoreStrategic or Co-development Partner · 3 November 2025Partnership to advance human-relevant CNS research. Co-hosted networking event at SfN 2025 in San Diego. Combines FUJIFILM's iCell neuronal products with Neuroservices-Alliance's electrophysiology expertise.
  • PhenoVista BiosciencesminorStrategic or Co-development Partner · 16 October 2024Strategic partnership announced to enhance CNS drug discovery services through complementary capabilities.
  • MaxWell BiosystemscoreTechnology or IntegrationStrategic partnership providing MaxWell Biosystems' HD-MEA technology (MaxTwo system) for high-content electrophysiology recording of human iPSC-derived neurons and other neuron cultures. Enables sub-cellular resolution recording with 26K+ electrodes per well.
  • Anatomic IncorporatedcoreTechnology or IntegrationCollaboration offering RealDRGTM cells from Anatomic for human DRG neuron research. Neuroservices-Alliance conducts studies using these cells for pain drug discovery applications.
  • Key-ObscoreStrategic or Co-development PartnerPreferred partner for in vivo models and behavioral tests. Key-Obs provides CNS disease models, behavioral phenotyping of transgenic mice, and screening assays for psychiatric, neurodegenerative, and other CNS disorders.
  • AnaBioscoreStrategic or Co-development PartnerMember company located in San Diego specializing in human tissue-based assays for safety and efficacy evaluation. Provides ex vivo human data including human DRG neurons from normal and chronic pain donors for pain drug discovery.
  • SynaxyscoreStrategic or Co-development PartnerCo-founded by Sophie Pautot, Synaxys specializes in preclinical in vitro human models including 3D engineered neuronal cell cultures for functional monitoring of brain models.
  • CHU de Bordeaux (Neurosurgeons)coreStrategic or Co-development PartnerPartnership with neurosurgeons from CHU of Bordeaux providing access to human brain tissue from resection surgeries for patch clamp recordings on pyramidal neurons, dentate gyrus neurons, and interneurons.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Neuroservices-Alliance competitors and assessment

Company assessment

Direct peers

  • AnaBios: AnaBios is a US-based CRO specializing in human tissue-based assays for drug discovery, including human DRG neurons and cardiomyocytes. It operates both as an integrated partner within the Neuroservices-Alliance consortium and as a direct provider of pain and safety pharmacology services to the same biopharma customers.
  • Porsolt: Porsolt is a French preclinical CRO offering CNS pharmacology services including behavioral models and electrophysiology for CNS drug discovery. It is a comparable small-to-mid sized French CNS CRO with overlapping customer base and similar service lines, particularly in behavioral and translational CNS pharmacology.
  • PsychoGenics: PsychoGenics is a US-based preclinical CRO specializing in CNS behavioral and electrophysiology services for psychiatric and neurodegenerative drug discovery. It is the closest direct competitor to Neuroservices-Alliance, operating in the same CNS preclinical niche with overlapping customer base in big-pharma neurology and psychiatry programs.
  • QPS Holdings: QPS is a mid-sized CRO with strong CNS and pain preclinical capabilities including electrophysiology, translational biomarkers, and in vivo CNS models. It is comparable to Neuroservices-Alliance in therapeutic-area focus and customer base, while also operating its own bioanalytical and clinical services lines.
  • SynapCell: SynapCell is a French preclinical CRO specialized in CNS electrophysiology, particularly in vivo and ex vivo recordings for epilepsy and neurodegenerative disease drug discovery. It is highly comparable to Neuroservices-Alliance in scale, therapeutic-area focus, and electrophysiology service offering, and operates in the same European CNS CRO segment.

Broad incumbents

  • Eurofins Scientific: Eurofins is one of the world's largest testing and contract research services groups, with a dedicated Discovery/CNS pharmacology arm offering electrophysiology and in vivo CNS studies. It overlaps with Neuroservices-Alliance on CNS preclinical services but competes mainly via scale, integrated platforms, and global lab footprint.
  • Labcorp Drug Development (Covance): Labcorp Drug Development is a global CRO offering preclinical and clinical research services including CNS pharmacology and safety assessment. It competes with Neuroservices-Alliance primarily at the enterprise level for integrated discovery-to-IND programs, but is much broader in scale and service scope.
  • Charles River Laboratories: Charles River is a global CRO with extensive preclinical CNS capabilities including safety assessment, electrophysiology, and in vivo pharmacology. It competes with Neuroservices-Alliance for enterprise-level CNS preclinical contracts but offers a far broader non-clinical service menu including toxicology and regulatory support.
  • Evotec: Evotec is a global drug discovery contract research and development organization offering CNS electrophysiology, in vitro/in vivo pharmacology, and integrated discovery services. It is comparable as a much larger broad-line CRO with overlapping CNS preclinical capabilities and similar biopharma customers, but with a significantly wider service portfolio.

Emerging players

  • Gubra: Gubra is a Danish preclinical CRO offering in vivo pharmacology, metabolic disease models, and CNS-related services. It is comparable to Neuroservices-Alliance as a mid-sized specialty CRO expanding into CNS and pain drug discovery, though it has stronger positioning in metabolic and endocrine areas.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Neuroservices-Alliance social profiles

Digital presence

Neuroservices-Alliance financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neuroservices-Alliance leadership team

Management profile

Number of profiles

Profiles11 records

Neuroservices-Alliance subsidiaries and ownership

Company hierarchy

Subsidiaries6 records

Neuroservices-Alliance funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neuroservices-Alliance M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neuroservices-Alliance

What does Neuroservices-Alliance do?

Neuroservices-Alliance is a Contract Research Organization (CRO) operating as a consortium of complementary CNS electrophysiology platforms that provide preclinical drug discovery services to pharmaceutical and biotech companies. Its core offerings span cell electrophysiology (patch-clamp, MEA, calcium imaging), 3D neural organoids, ex vivo brain slice electrophysiology, in vivo brain electrophysiology, and in vivo spinal cord and DRG electrophysiology, supporting CNS and pain therapeutic programs from target validation through translational studies.

Is Neuroservices-Alliance a public or private company?

Neuroservices-Alliance is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Neuroservices-Alliance founded?

Neuroservices-Alliance was founded in 2018. It employs 11 to 50 people.

Where is Neuroservices-Alliance based?

Neuroservices-Alliance is headquartered in San Diego, United States, in the North America region.

How does Neuroservices-Alliance make money?

One revenue line is on record: preclinical Contract Research Services.

Who are Neuroservices-Alliance's main competitors?

Direct peers on record are AnaBios, Porsolt, PsychoGenics, QPS Holdings and SynapCell. Broad incumbents are Eurofins Scientific, Labcorp Drug Development (Covance), Charles River Laboratories and Evotec. Gubra is listed as an emerging player.

Does Neuroservices-Alliance have an API?

No public API is recorded for Neuroservices-Alliance.

What industry is Neuroservices-Alliance in?

Neuroservices-Alliance's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK), with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales